• Project Leader: Dr Vijay Kunadian

In brief the EVoLVeD-AS study will screen approximately 1500 people with asymptomatic advanced aortic stenosis (AV Vmax >3.5m/s) using a combination of high sensitivity troponin I and ECG. Those with positive screening results will undergo cardiac MRI and if mid-wall fibrosis is present on late gadolinium enhancement sequences they will be randomised (1:1) to routine care (watchful waiting) or early aortic valve intervention. We are aiming to randomise 400 patients in total. The planned follow up is three years using a combination of telephone consultation and screening of electronic records to detect adverse events. The primary outcome will be a composite of all-cause mortality and AS-related unplanned hospital admission. We are aiming to start recruitment early 2017 for a period of 18-24 months.

Project Leader: Dr Vijay Kunadian